This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Niguldipine
Accession Number
DB09239
Type
Small Molecule
Groups
Experimental
Description

Niguldipine is a calcium channel blocker and a1-adrenergic receptor antagonist.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Niguldipine hydrochloride1G8C7QS9SR113145-69-0MHOSUIMBPQVOEU-WAQYZQTGSA-N
Categories
UNII
Z81N45O25Z
CAS number
113165-32-5
Weight
Average: 609.723
Monoisotopic: 609.283885988
Chemical Formula
C36H39N3O6
InChI Key
SVJMLYUFVDMUHP-XIFFEERXSA-N
InChI
InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m0/s1
IUPAC Name
3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
[H]N1C(C)=C([C@H](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Niguldipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Niguldipine.Vet Approved
4-MethoxyamphetamineNiguldipine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Niguldipine.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Niguldipine.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
AdrafinilNiguldipine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineNiguldipine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Niguldipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Niguldipine.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Withdrawn
AmbrisentanNiguldipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronNiguldipine may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineNiguldipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
AmitrazNiguldipine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Niguldipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Niguldipine.Approved
AmobarbitalThe metabolism of Niguldipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Niguldipine.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Niguldipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Niguldipine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Niguldipine.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Niguldipine is combined with Amrinone.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Niguldipine.Approved, Investigational, Withdrawn
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Niguldipine.Approved, Investigational
AnisodamineNiguldipine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineNiguldipine may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineNiguldipine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Aranidipine.Approved, Investigational
ArbutamineNiguldipine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolNiguldipine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Niguldipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Niguldipine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Niguldipine.Approved
AsenapineAsenapine may increase the antihypertensive activities of Niguldipine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
AvanafilAvanafil may increase the hypotensive activities of Niguldipine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Niguldipine is combined with Azimilide.Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Niguldipine.Experimental
BambuterolNiguldipine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Niguldipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Niguldipine can be increased when combined with Barbital.Illicit
BarnidipineNiguldipine may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Niguldipine.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Niguldipine is combined with Bencyclane.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Niguldipine.Approved
BenidipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Niguldipine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Niguldipine.Approved, Investigational
BenzphetamineNiguldipine may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilBepridil may increase the hypotensive activities of Niguldipine.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Niguldipine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Niguldipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Niguldipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Niguldipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Niguldipine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
BitolterolNiguldipine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
BosentanBosentan may increase the hypotensive activities of Niguldipine.Approved, Investigational
BQ-123Niguldipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Niguldipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Niguldipine.Approved
BrexpiprazoleNiguldipine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Niguldipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Niguldipine.Experimental
BromocriptineNiguldipine may decrease the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Niguldipine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Niguldipine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Niguldipine.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Niguldipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Niguldipine.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Niguldipine.Experimental
CafedrineNiguldipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanNiguldipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Niguldipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Niguldipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Niguldipine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Niguldipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Niguldipine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Niguldipine is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Niguldipine is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Niguldipine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Niguldipine.Approved, Investigational
CaseinThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Niguldipine.Approved
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Niguldipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Niguldipine.Approved
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Niguldipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Niguldipine.Approved
CicletanineNiguldipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Niguldipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Niguldipine.Approved
CilnidipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Niguldipine can be increased when it is combined with Cimetidine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Niguldipine is combined with Cinnarizine.Approved, Investigational
CirazolineNiguldipine may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolNiguldipine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Clevidipine.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Niguldipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Niguldipine.Approved, Vet Approved
ClozapineClozapine may increase the antihypertensive activities of Niguldipine.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Niguldipine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Niguldipine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Niguldipine is combined with Cyclandelate.Approved
CyclopenthiazideNiguldipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Niguldipine.Approved
CymarinCymarin may decrease the cardiotoxic activities of Niguldipine.Experimental
DapiprazoleDapiprazole may increase the antihypertensive activities of Niguldipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Niguldipine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Niguldipine.Approved, Investigational
DelaprilNiguldipine may increase the hypotensive activities of Delapril.Investigational
DeserpidineNiguldipine may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Niguldipine.Approved
DetomidineNiguldipine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineNiguldipine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineNiguldipine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Niguldipine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Niguldipine.Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Niguldipine.Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Niguldipine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Niguldipine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Niguldipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Niguldipine.Approved, Investigational
DihydroergotamineNiguldipine may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Niguldipine.Approved, Investigational
DipivefrinNiguldipine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Niguldipine.Approved
DL-MethylephedrineNiguldipine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineNiguldipine may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.Approved, Investigational
DopexamineNiguldipine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Niguldipine.Approved
DotarizineThe risk or severity of hypotension can be increased when Niguldipine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Niguldipine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Niguldipine.Approved, Investigational
DoxofyllineNiguldipine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneDronedarone may increase the antihypertensive activities of Niguldipine.Approved
DroperidolDroperidol may increase the antihypertensive activities of Niguldipine.Approved, Vet Approved
DroxidopaNiguldipine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Niguldipine.Approved
EfavirenzThe serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Niguldipine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
EnalaprilatNiguldipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Niguldipine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Niguldipine is combined with Eperisone.Approved, Investigational
EphedraNiguldipine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineNiguldipine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineNiguldipine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineNiguldipine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Niguldipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Niguldipine.Approved
ErgonovineNiguldipine may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineNiguldipine may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Niguldipine.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
EtafedrineNiguldipine may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Niguldipine is combined with Ethosuximide.Approved
EtilefrineNiguldipine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateNiguldipine may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineFelodipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Niguldipine is combined with Fendiline.Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Niguldipine.Approved
FenoterolNiguldipine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Niguldipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Niguldipine.Experimental
Fish oilThe risk or severity of hypotension can be increased when Niguldipine is combined with Fish oil.Approved, Nutraceutical
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Niguldipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Niguldipine.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Niguldipine is combined with Flunarizine.Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Niguldipine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Niguldipine is combined with Fluspirilene.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Niguldipine.Experimental
FormoterolNiguldipine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Niguldipine.Approved
FostamatinibFostamatinib may increase the hypotensive activities of Niguldipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Niguldipine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Niguldipine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Niguldipine is combined with Gallopamil.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Niguldipine.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Niguldipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Niguldipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Niguldipine.Approved
GuanazodineNiguldipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Niguldipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Niguldipine.Approved, Investigational
GuanoclorNiguldipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNiguldipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNiguldipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Niguldipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Niguldipine.Approved, Withdrawn
HarmalineHarmaline may increase the hypotensive activities of Niguldipine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Niguldipine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Niguldipine.Approved, Investigational
HexobarbitalThe metabolism of Niguldipine can be increased when combined with Hexobarbital.Approved
HexoprenalineNiguldipine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineNiguldipine may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Niguldipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Niguldipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Niguldipine.Approved, Investigational
IloperidoneIloperidone may increase the antihypertensive activities of Niguldipine.Approved
IloprostIloprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
ImidaprilNiguldipine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may increase the antihypertensive activities of Niguldipine.Approved
IndacaterolNiguldipine may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideIndapamide may increase the hypotensive activities of Niguldipine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Niguldipine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Niguldipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Niguldipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Niguldipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Niguldipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Niguldipine.Approved
IsoetarineNiguldipine may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneNiguldipine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineNiguldipine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineNiguldipine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Niguldipine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Niguldipine.Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Niguldipine.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Niguldipine.Approved
LacidipineLacidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Niguldipine is combined with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Niguldipine.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Niguldipine.Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Niguldipine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
LevosalbutamolNiguldipine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Niguldipine is combined with Lidoflazine.Experimental
LinsidomineNiguldipine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineNiguldipine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Niguldipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Niguldipine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Niguldipine is combined with Loperamide.Approved
LosartanLosartan may increase the hypotensive activities of Niguldipine.Approved
MacitentanNiguldipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Niguldipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MedetomidineNiguldipine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Niguldipine is combined with Menthol.Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Niguldipine.Experimental
MephentermineNiguldipine may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
MetaraminolNiguldipine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetamineNiguldipine may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Niguldipine can be increased when combined with Methohexital.Approved
MethoserpidineNiguldipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Niguldipine.Approved, Investigational
MethoxamineNiguldipine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineNiguldipine may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Niguldipine is combined with Methsuximide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Niguldipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Niguldipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Niguldipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Niguldipine can be increased when combined with Methylphenobarbital.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Niguldipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Niguldipine.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
MetyrosineNiguldipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Niguldipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Niguldipine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Niguldipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
MidodrineNiguldipine may decrease the vasoconstricting activities of Midodrine.Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Niguldipine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Niguldipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Niguldipine.Approved, Investigational
MirabegronNiguldipine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Niguldipine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Niguldipine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Niguldipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Niguldipine.Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MuzolimineNiguldipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Niguldipine.Experimental
NadololNadolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
NafcillinThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Niguldipine.Approved
NaftopidilNiguldipine may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNiguldipine may decrease the vasoconstricting activities of Naphazoline.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Niguldipine.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Niguldipine.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Niguldipine.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Niguldipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Niguldipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Niguldipine.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Niguldipine.Investigational
NiludipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Niludipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Niguldipine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Niguldipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
NitroprussideNiguldipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Niguldipine.Approved
NorepinephrineNiguldipine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineNiguldipine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineNortriptyline may increase the antihypertensive activities of Niguldipine.Approved
NylidrinNiguldipine may decrease the vasoconstricting activities of Nylidrin.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Niguldipine.Approved, Vet Approved
ObinutuzumabNiguldipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Niguldipine.Withdrawn
OctopamineNiguldipine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Niguldipine.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Niguldipine.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
OlodaterolNiguldipine may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Niguldipine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Niguldipine.Experimental
OrciprenalineNiguldipine may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Niguldipine is combined with Otilonium.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Niguldipine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Niguldipine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
OxyfedrineNiguldipine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineNiguldipine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Niguldipine.Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Niguldipine.Approved
PargylinePargyline may increase the hypotensive activities of Niguldipine.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Niguldipine.Approved, Investigational
PentobarbitalThe metabolism of Niguldipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Niguldipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Niguldipine.Approved, Investigational
PergolideNiguldipine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Niguldipine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Niguldipine.Experimental
PhendimetrazineNiguldipine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Niguldipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Niguldipine.Withdrawn
PhenobarbitalThe metabolism of Niguldipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Niguldipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Niguldipine.Withdrawn
PhentolaminePhentolamine may increase the antihypertensive activities of Niguldipine.Approved
PhenylephrineNiguldipine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineNiguldipine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Niguldipine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Niguldipine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
PirbuterolNiguldipine may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Niguldipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Niguldipine.Withdrawn
PizotifenNiguldipine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Niguldipine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Niguldipine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
PrazosinPrazosin may increase the antihypertensive activities of Niguldipine.Approved
PrenalterolNiguldipine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Niguldipine is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Niguldipine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Niguldipine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Niguldipine.Approved, Investigational
ProcaterolNiguldipine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazinePromazine may increase the antihypertensive activities of Niguldipine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Niguldipine.Approved
PropericiazineNiguldipine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Niguldipine.Approved
PropiverineNiguldipine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Niguldipine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Niguldipine.Experimental
ProtokylolNiguldipine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrineNiguldipine may decrease the vasoconstricting activities of Pseudoephedrine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Niguldipine.Experimental
QuetiapineQuetiapine may increase the antihypertensive activities of Niguldipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Niguldipine.Approved, Investigational
QuinidineNiguldipine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Niguldipine.Approved
RacepinephrineNiguldipine may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineNiguldipine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Niguldipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Niguldipine.Approved
RasagilineRasagiline may increase the hypotensive activities of Niguldipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Niguldipine.Approved
ReproterolNiguldipine may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineNiguldipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Niguldipine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Niguldipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Niguldipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Niguldipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Niguldipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Niguldipine.Approved, Investigational
RimiterolNiguldipine may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatNiguldipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the antihypertensive activities of Niguldipine.Approved, Investigational
RitobegronNiguldipine may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineNiguldipine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabNiguldipine may increase the hypotensive activities of Rituximab.Approved
RomifidineNiguldipine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleNiguldipine may decrease the vasoconstricting activities of Ropinirole.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Niguldipine.Withdrawn
SalbutamolNiguldipine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Niguldipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
SalmeterolNiguldipine may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Niguldipine.Experimental
SecobarbitalThe metabolism of Niguldipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Niguldipine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Niguldipine is combined with Seletracetam.Investigational
SelexipagNiguldipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Niguldipine.Approved, Investigational
SildenafilSildenafil may increase the hypotensive activities of Niguldipine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Niguldipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Niguldipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Niguldipine.Approved, Investigational
SitaxentanNiguldipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronNiguldipine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Niguldipine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Niguldipine.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Niguldipine.Approved
SynephrineNiguldipine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Niguldipine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Niguldipine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Niguldipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Niguldipine.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Niguldipine.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Niguldipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Niguldipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Niguldipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Niguldipine.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Niguldipine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
TetrahydropalmatineNiguldipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineNiguldipine may decrease the vasoconstricting activities of Tetryzoline.Approved
TheodrenalineNiguldipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the hypotensive activities of Niguldipine.Approved
ThiamylalThe metabolism of Niguldipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Niguldipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the antihypertensive activities of Niguldipine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Niguldipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Niguldipine.Approved
TiboloneTibolone may increase the hypotensive activities of Niguldipine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Niguldipine.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Niguldipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Niguldipine.Approved
TizanidineNiguldipine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Niguldipine.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Niguldipine.Experimental
Tolfenamic AcidThe risk or severity of hypotension can be increased when Niguldipine is combined with Tolfenamic Acid.Approved, Investigational
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Niguldipine.Approved, Investigational, Vet Approved
TolonidineNiguldipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Niguldipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Niguldipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Niguldipine.Approved
TranilastThe risk or severity of hypotension can be increased when Niguldipine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Niguldipine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Niguldipine.Approved
TrazodoneTrazodone may increase the antihypertensive activities of Niguldipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Niguldipine.Approved, Investigational
TretoquinolNiguldipine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Niguldipine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Niguldipine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Niguldipine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Niguldipine is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Niguldipine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Niguldipine.Approved, Investigational
TrimipramineTrimipramine may increase the antihypertensive activities of Niguldipine.Approved
TulobuterolNiguldipine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Niguldipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Niguldipine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Niguldipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Niguldipine.Approved
VerapamilNiguldipine may increase the antihypertensive activities of Verapamil.Approved
VilanterolNiguldipine may decrease the vasoconstricting activities of Vilanterol.Approved
VincamineNiguldipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNiguldipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Niguldipine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Niguldipine is combined with WIN 55212-2.Experimental
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Niguldipine.Experimental
XamoterolNiguldipine may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideNiguldipine may increase the hypotensive activities of Xipamide.Experimental
XylazineNiguldipine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineXylometazoline may increase the hypotensive activities of Niguldipine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Niguldipine.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Niguldipine is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Niguldipine.Approved
ZofenoprilNiguldipine may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Niguldipine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Niguldipine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Boer R, Grassegger A, Schudt C, Glossmann H: (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131-45. [PubMed:2548881]
External Links
PubChem Compound
60602
PubChem Substance
310265142
ChemSpider
54630
BindingDB
50453799
ChEBI
103931
ChEMBL
CHEMBL405355
Wikipedia
Niguldipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000113 mg/mLALOGPS
logP6.27ALOGPS
logP5.6ChemAxon
logS-6.7ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)9.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.01 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity185.9 m3·mol-1ChemAxon
Polarizability66.15 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylpiperidines / Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives
show 10 more
Substituents
Diphenylmethane / Phenylpiperidine / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Nitroaromatic compound / Aralkylamine / Dihydropyridine / Piperidine / Hydropyridine / Dicarboxylic acid or derivatives
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249]

Drug created on October 23, 2015 11:02 / Updated on July 02, 2018 20:51